BrainsWay Selected to Participate in FDA Innovation Challenge: Devices to Prevent and Treat Opioid Use Disorder

BrainsWay Selected to Participate in FDA Innovation Challenge: Devices to Prevent and Treat Opioid Use Disorder

12/10/2018

HACKENSACK, N.J., Dec. 10, 2018 (GLOBE NEWSWIRE) — BrainsWay Ltd. (BRIN.TA), the parent company of BrainsWay USA, Inc., and a global leader in the advanced non-invasive treatment of brain disorders, today announces that the Company’s deep transcranial magnetic stimulation (Deep TMS) system was one of only eight medical devices selected by the U.S. Food and Drug Administration (FDA) from over 250 applications to participate in the “FDA Innovation Challenge: Devices to Prevent and Treat Opioid Use Disorder,” a new program launched by the FDA to help combat the opioid crisis.

Call Now Button